Holen Sie sich die Stockscreener-App
25.50
0.86%
-0.22
Handel nachbörslich:
25.50
Schlusskurs vom Vortag:
$25.72
Offen:
$25.66
24-Stunden-Volumen:
1.67M
Relative Volume:
0.92
Marktkapitalisierung:
$4.30B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
141.67
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-2.78%
1M Leistung:
+6.07%
6M Leistung:
+39.65%
1J Leistung:
+52.79%
1-Tages-Spanne:
$25.21
$25.68
1-Wochen-Bereich:
$25.21
$26.50
52-Wochen-Spanne:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.50 | 4.33B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals Inc. recovery potential after sell offMarket Trend Report & Weekly High Conviction Trade Ideas - Newser
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial - MSN
Should you avoid ACADIA Pharmaceuticals Inc. stock right nowPortfolio Performance Report & High Conviction Buy Zone Alerts - khodrobank.com
Pattern recognition hints at ACADIA Pharmaceuticals Inc. upsideJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Trend analysis for ACADIA Pharmaceuticals Inc. this weekQuarterly Profit Report & Free Technical Pattern Based Buy Signals - Newser
Analyzing drawdowns of ACADIA Pharmaceuticals Inc. with statistical toolsJuly 2025 Rallies & Real-Time Volume Spike Alerts - Newser
Statistical indicators supporting ACADIA Pharmaceuticals Inc.’s strengthMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Using data models to predict ACADIA Pharmaceuticals Inc. stock movement2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - Newser
Sector ETF performance correlation with ACADIA Pharmaceuticals Inc.Bond Market & Real-Time Stock Movement Alerts - Newser
Signal strength of ACADIA Pharmaceuticals Inc. stock in tech scannersTrade Ideas & Verified Technical Signals - Newser
Director Sells Shares in ACADIA Pharmaceuticals - TipRanks
Is ACADIA Pharmaceuticals Inc. forming a reversal patternMarket Risk Analysis & Verified High Yield Trade Plans - Newser
Acadia Pharmaceuticals director Garofalo sells $41,560 in stock - Investing.com
Can swing trading help recover from ACADIA Pharmaceuticals Inc. losses2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
Glioblastoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - The Globe and Mail
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer - CDO Magazine
Market reaction to ACADIA Pharmaceuticals Inc.’s recent newsQuarterly Portfolio Report & Weekly Setup with ROI Potential - Newser
Key metrics from ACADIA Pharmaceuticals Inc.’s quarterly dataWeekly Stock Recap & Accurate Buy Signal Alerts - Newser
Is ACADIA Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
What is ACADIA Pharmaceuticals Inc.’s valuation compared to sector2025 Geopolitical Influence & Weekly High Return Stock Opportunities - khodrobank.com
Is ACADIA Pharmaceuticals Inc. vulnerable to short sellersTrade Analysis Summary & Growth Focused Stock Pick Reports - khodrobank.com
Price action breakdown for ACADIA Pharmaceuticals Inc.2025 Biggest Moves & AI Powered Market Entry Strategies - Newser
ACADIA Pharmaceuticals Inc. stock chart pattern explained2025 Volume Leaders & Verified Entry Point Signals - Newser
How to manage a losing position in ACADIA Pharmaceuticals Inc.2025 Market WrapUp & Stepwise Trade Signal Guides - Newser
Is ACADIA Pharmaceuticals Inc. in a consolidation phase2025 Market Outlook & Community Shared Stock Ideas - khodrobank.com
Can ACADIA Pharmaceuticals Inc. sustain its profitabilityJuly 2025 Review & Low Drawdown Investment Strategies - khodrobank.com
ACADIA Pharmaceuticals Inc. stock daily chart insights2025 Historical Comparison & Reliable Trade Execution Plans - Newser
Does ACADIA Pharmaceuticals Inc. show high probability of rebound2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
ACADIA Pharmaceuticals Inc. stock volume spike explainedTreasury Yields & Proven Capital Preservation Tips - Newser
Can machine learning forecast ACADIA Pharmaceuticals Inc. recoveryWeekly Market Report & Low Drawdown Momentum Ideas - Newser
How to integrate ACADIA Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Gainers & Consistent Growth Equity Picks - Newser
Institutional scanner results for ACADIA Pharmaceuticals Inc.July 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Published on: 2025-08-30 06:46:07 - Newser
Using portfolio simulators with ACADIA Pharmaceuticals Inc. includedWeekly Trade Recap & Scalable Portfolio Growth Methods - Newser
Published on: 2025-08-29 17:29:10 - Newser
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acadia Pharmaceuticals Inc-Aktie (ACAD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 18 '25 |
Sale |
25.18 |
22,000 |
554,024 |
40,130 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):